COMPANY INTELLIGENCE PROFILE
TATA 1MG HEALTHCARE SOLUTIONS PRIVATE LIMITED
Tata 1mg's pharmaceutical trading/distribution entity — part of the Tata Digital-owned "Tata 1mg" online pharmacy and digital healthcare platform.
TATA 1MG Healthcare Solutions Private Limited is an active entity, part of Tata 1mg's online pharmacy and digital healthcare platform owned by Tata Digital Private Limited. Incorporated on July 6, 2016, the company focuses on trading and distributing pharmaceutical products. In FY2024-25, it reported a revenue of approximately ₹2,019.69 crore, with a modest positive net profit margin and increased assets. Legal engagements are primarily in commercial arbitration matters.
AI-generated, may contain errors.
Business Overview
- Tata 1mg Healthcare Solutions Private Limited is part of the "Tata 1mg" integrated healthcare platform, majority-owned by Tata Digital Private Limited since the 2021 acquisition of the original 1mg business.
- Per Tofler's registry description, this entity's core activity is trading/distribution of generic drugs and pharmaceutical products, capsules, syrups, suspensions, drops, tablets, injections, dry syrup, ointments, protein powders.
- Commercially, "Tata 1mg" operates as India's e-pharmacy and digital healthcare ecosystem offering online medicine ordering with home delivery, lab/diagnostic testing with home sample collection, teleconsultations, health devices, vaccination-at-home, and subscription health plans, source: 1mg.com, company website.
- Note: it is not fully certain whether all consumer-facing platform operations (app/tech) sit inside this exact CIN vs. a sibling/parent entity — see financials note below, partial confidence on the precise business-activity/entity boundary.
Sector & Classification
Business: retail/wholesale trade and distribution of pharmaceuticals (generic drugs, capsules, syrups, tablets, injections, ointments) per Tofler business description; registered CIN's NIC prefix (47721) = "Retail sale of medical and orthopaedic goods." Note: Tofler separately displayed an inconsistent "Activity Group J — Information & Communication" tag on one page, which conflicts with the NIC-code-implied retail/pharma classification — likely a platform categorization glitch; treat the pharma-retail/distribution classification as the reliable one (partial confidence on exact NIC due to this conflict).
Directors & Key Management
Directors — source notes
Confirmed (name-level, ≥2 sources — Tofler, TheCompanyCheck, and partially Falconebiz): Tanmay Saksena (Director, appointed 01 Nov 2017), Gaurav Agarwal (Director, appointed 28 Jun 2021), Nikhil Doegar (Director, appointed 14 Jun 2023). DINs (single-source, Tofler only — treat as partial confidence, not cross-confirmed): Tanmay Saksena DIN 03623581; Gaurav Agarwal DIN 07497713; Nikhil Doegar DIN 10175087. No DINs were independently corroborated by a second source in this pass.
GST Registrations
Not obtained. A plausible GSTIN was not confirmed on any individual GSTIN lookup page (knowyourgst/mastersindia lookups by constructed GSTIN and by PAN returned no data/404). Per rules, no GSTIN is reported rather than guessed from the PAN. Primary GSTIN, home state (expected Delhi, code 07), registration count and status: not obtained.
Financials
Tata 1MG Healthcare Solutions Private Limited reported standalone revenue of approximately ₹2,019.69 Cr for FY2024-25, marking a 17% increase year-over-year. The company posted a small net profit with a net profit margin of 2.67%, while borrowings and assets grew by 28.04% and 35.37% respectively.
AI-generated, may contain errors.
- FY2024-25, year ended 31 Mar 2025, standalone, per Tofler/TheCompanyCheck registry filings, both agree, partial-confirmed on revenue only: Revenue ≈ ₹2,019.69 Cr, TheCompanyCheck, / ₹2,000-2,250 Cr range (Tofler), up ~17% YoY.
- Tofler ratios (Mar-2025): Gross margin 0.96%, Operating margin 2.41%, Net profit margin 2.67%, implies a small positive net profit, roughly ₹50-55 Cr, on a standalone basis, ROCE -62.23%, Debt-to-equity 0.08, borrowings up 28.04% YoY, assets up 35.37% YoY.
- EBITDA and absolute PAT/net-worth figures were paywalled ("Tofler Pro") and not obtained.
- IMPORTANT ENTITY-CONFUSION CAUTION: press coverage (Inc42) widely reports large losses for "Tata 1mg" — FY22 loss ₹526 Cr, FY23 loss ₹1,259 Cr, FY24 loss ₹313 Cr — but these figures are inconsistent with the small POSITIVE net margin shown by the registry filing for this exact CIN, Tata 1Mg Healthcare Solutions Private Limited, in FY25.
- This strongly suggests the widely-reported loss figures belong to a different group entity, likely "1MG Technologies Private Limited," the original/consolidated 1mg entity or holding company, rather than to this specific subsidiary CIN.
- The loss figures are NOT attributed to this entity in this profile to avoid the entity-confusion trap
- They are noted only as a caution for the SEO page author.
Funding History
- Not directly attributable to this exact CIN with confidence — funding/M&A activity is documented for the broader "1mg"/"Tata 1mg" business, not confirmed as booked into this specific subsidiary.
- Per Inc42: Tata Digital Private Limited, Tata Sons' digital arm, acquired a majority stake in 1mg in June 2021, deal value widely reported in press at the time as ~$200-250 Mn, not independently re-confirmed in this pass — treat as unconfirmed/partial.
- A further $40 Mn round led by Tata Digital was reported in September 2022, after which "Tata 1mg" was described in press as having crossed unicorn ($1Bn+) valuation.
- Use Tracxn only for round-name/date corroboration if needed
- Not independently re-verified here.
Loans & Charges
- Conflicting data between two sources — flagged, not resolved in this pass: (a) TheCompanyCheck states 0 open charges and ₹88.1 Cr in satisfied charges across six charge instances, ranging ₹5-40 Cr each, dated 2018-2021, lender type listed only as "Others," lender names not disclosed
- (b) Tofler's charges page states "the company has no registered charges" at all. Given the conflict, charge history should be treated as partial/unconfirmed pending a primary MCA filing check, not performed — MCA is on the blocked-source list for this task.
Credit Ratings
- Not obtained. No CRISIL, ICRA, or CARE rating for "Tata 1mg Healthcare Solutions Private Limited" or "1mg Technologies" could be located via direct site lookup in this pass.
Legal & Compliance
- Confirmed, Indian Kanoon, Delhi High Court orders — entity named directly in each case, so reliably attributable to this company: (1) Qrg Medicare Private Limited vs Tata 1Mg Healthcare Solutions Private Limited — Delhi HC, order dated 01 Aug 2025, Justice Purushaindra Kumar Kaurav
- (2) Tata 1Mg Healthcare Solutions Private Limited vs Ritu Dua, Proprietor, Shree Aditya, — Delhi HC, O.M.P. (MISC.) (COMM.) 504/2023, order dated 11 Oct 2023, Justice Sachin Datta
- (3) Tata 1Mg Healthcare Solutions Private Limited vs Marengo Asia Healthcare Private Limited — Delhi HC, ARB.P. 1118/2025 & I.A. 18383/2025, order dated 31 Jul 2025
- (4) North East Healthcare Private Limited vs Tata 1Mg Healthcare Solutions Private Limited — Delhi HC, order dated 07 Aug 2025
- (5) Marengo Asia Healthcare Private Limited vs Tata 1Mg Healthcare Solutions Private Limited — Delhi HC, order dated 07 Aug 2025
- (6) Qrg Medicare Private Limited vs Tata 1Mg Healthcare Solutions Private Limited — Delhi HC, order dated 07 Aug 2025. Mostly commercial/arbitration matters
- No criminal or regulatory-penalty orders surfaced., Separately, press has reported DCGI regulatory notices to e-pharmacies including Tata 1mg in Feb 2023 — not independently verified via a legal filing in this pass, noted as context only.
Competitive Landscape
- PharmEasy (API Holdings) — large-scale e-pharmacy/diagnostics peer, comparable/larger scale historically
- Netmeds, Reliance Retail-owned, — large-scale e-pharmacy peer
- Apollo 24|7, Apollo Hospitals' digital arm, — large integrated healthcare peer
- MedPlus Mart / Medlife — large pharmacy retail chain + e-pharmacy
- Truemeds — mid-scale generics-focused e-pharmacy, smaller scale
- Practo — mid-scale, telemedicine/doctor-discovery focused rather than pharmacy-first.
Frequently Asked Questions
What does TATA 1MG HEALTHCARE SOLUTIONS PRIVATE LIMITED do?
TATA 1MG HEALTHCARE SOLUTIONS PRIVATE LIMITED is involved in the retail and wholesale trade and distribution of generic drugs and pharmaceutical products, such as capsules, syrups, tablets, and ointments. It operates as part of Tata 1mg, an e-pharmacy and digital healthcare platform.
What is the CIN of TATA 1MG HEALTHCARE SOLUTIONS PRIVATE LIMITED?
The CIN (Corporate Identification Number) of TATA 1MG HEALTHCARE SOLUTIONS PRIVATE LIMITED is U24290DL2016PTC302634.
When was TATA 1MG HEALTHCARE SOLUTIONS PRIVATE LIMITED incorporated?
TATA 1MG HEALTHCARE SOLUTIONS PRIVATE LIMITED was incorporated on 06 July 2016.
Where is the registered office of TATA 1MG HEALTHCARE SOLUTIONS PRIVATE LIMITED located?
The registered office of TATA 1MG HEALTHCARE SOLUTIONS PRIVATE LIMITED is located at 2nd Floor, Plot No. B-225, Okhla Industrial Area, Phase-I, New Delhi, Delhi 110020.
Sources
Tofler (tofler.in) — company detail, financials, charges, shareholders pages; TheCompanyCheck (thecompanycheck.com) — company detail page; Falconebiz (falconebiz.com) — attempted, homepage only, no company-level data retrieved; Indian Kanoon (indiankanoon.org) — litigation search; 1mg.com — official website (business overview, logo); Inc42 (inc42.com) — funding/financial press coverage archive (used with entity-confusion caution flagged). Attempted and returned no data: knowyourgst.com, mastersindia.co (GSTIN lookups), crisilratings.com (ratings lookup).
Information compiled from public registry and secondary sources. It may be incomplete or dated; verify independently before relying on it.